The funds will support the firm's lead programs, ABS-1230 for KCNT1-related epilepsy and ABS-0871 for TRPV4-positive Charcot-Marie-Tooth disease type 2C.

In the growing rare disease precision medicine market, drug companies must avoid funding genetic testing that the Justice ...

Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

The partners have committed to awarding two grants, totaling around $2.3 million, to researchers studying this lung cancer subset.